The webinars will provide participants with patient-relevant information on newly approved multiple myeloma treatment agents, options for and implications of participating in clinical trials, and new strategies that may be available for prolonging their response to treatment. The information in these activities will empower participants to advocate for achieving the best possible outcome for their disease.